99 related articles for article (PubMed ID: 7719242)
1. Sequential phenotyping of myeloma patients on chemotherapy: persistence of activated T-cells and natural killer cells.
Kay NE; Oken MM; Kyle R; Van Ness B; Kalish L; Leong T; Greipp P
Leuk Lymphoma; 1995 Jan; 16(3-4):351-4. PubMed ID: 7719242
[TBL] [Abstract][Full Text] [Related]
2. The addition of interferon or high dose cyclophosphamide to standard chemotherapy in the treatment of patients with multiple myeloma: phase III Eastern Cooperative Oncology Group Clinical Trial EST 9486.
Oken MM; Leong T; Lenhard RE; Greipp PR; Kay NE; Van Ness B; Keimowitz RM; Kyle RA
Cancer; 1999 Sep; 86(6):957-68. PubMed ID: 10491521
[TBL] [Abstract][Full Text] [Related]
3. Complete remission induction with combined VBMCP chemotherapy and interferon (rIFN alpha 2b) in patients with multiple myeloma.
Oken MM; Kyle RA; Greipp PR; Kay NE; Tsiatis A; Gregory SA; Spiegel R J; O'Connell M J
Leuk Lymphoma; 1996 Feb; 20(5-6):447-52. PubMed ID: 8833401
[TBL] [Abstract][Full Text] [Related]
4. Blood levels of immune cells predict survival in myeloma patients: results of an Eastern Cooperative Oncology Group phase 3 trial for newly diagnosed multiple myeloma patients.
Kay NE; Leong TL; Bone N; Vesole DH; Greipp PR; Van Ness B; Oken MM; Kyle RA
Blood; 2001 Jul; 98(1):23-8. PubMed ID: 11418458
[TBL] [Abstract][Full Text] [Related]
5. Comparison of melphalan and prednisone with vincristine, carmustine, melphalan, cyclophosphamide, and prednisone in the treatment of multiple myeloma: results of Eastern Cooperative Oncology Group Study E2479.
Oken MM; Harrington DP; Abramson N; Kyle RA; Knospe W; Glick JH
Cancer; 1997 Apr; 79(8):1561-7. PubMed ID: 9118039
[TBL] [Abstract][Full Text] [Related]
6. Flow cytometric characterization of human umbilical cord blood lymphocytes: immunophenotypic features.
D'Arena G; Musto P; Cascavilla N; Di Giorgio G; Fusilli S; Zendoli F; Carotenuto M
Haematologica; 1998 Mar; 83(3):197-203. PubMed ID: 9573672
[TBL] [Abstract][Full Text] [Related]
7. Lymphocyte recovery and clinical response in multiple myeloma patients receiving interferon alpha 2 beta after intensive therapy.
Millar BC; Bell JB; Powles RL
Br J Cancer; 1996 Jan; 73(2):236-40. PubMed ID: 8546912
[TBL] [Abstract][Full Text] [Related]
8. Immune status of high-risk smoldering multiple myeloma patients and its therapeutic modulation under LenDex: a longitudinal analysis.
Paiva B; Mateos MV; Sanchez-Abarca LI; Puig N; Vidriales MB; López-Corral L; Corchete LA; Hernandez MT; Bargay J; de Arriba F; de la Rubia J; Teruel AI; Giraldo P; Rosiñol L; Prosper F; Oriol A; Hernández J; Esteves G; Lahuerta JJ; Bladé J; Perez-Simon JA; San Miguel JF;
Blood; 2016 Mar; 127(9):1151-62. PubMed ID: 26668134
[TBL] [Abstract][Full Text] [Related]
9. Chemotherapy markedly reduces B cells but not T cells and NK cells in patients with cancer.
Waidhauser J; Schuh A; Trepel M; Schmälter AK; Rank A
Cancer Immunol Immunother; 2020 Jan; 69(1):147-157. PubMed ID: 31900508
[TBL] [Abstract][Full Text] [Related]
10. The interaction of maintenance interferon with cytolytic cells in patients with multiple myeloma who responded to cytotoxic chemotherapy.
Hall PD; Self SE; Hall RK
Pharmacotherapy; 1997; 17(2):248-55. PubMed ID: 9085315
[TBL] [Abstract][Full Text] [Related]
11. Lymphocytic subpopulation changes after open and laparoscopic cholecystectomy: a prospective and comparative study on 38 patients.
Cristaldi M; Rovati M; Elli M; Gerlinzani S; Lesma A; Balzarotti L; Taschieri AM
Surg Laparosc Endosc; 1997 Jun; 7(3):255-61. PubMed ID: 9194291
[TBL] [Abstract][Full Text] [Related]
12. Natural killer cells and CD56+ T cells in the blood of multiple myeloma patients: analysis by 4-colour flow cytometry.
King MA; Radicchi-Mastroianni MA
Cytometry; 1996 Jun; 26(2):121-4. PubMed ID: 8817087
[TBL] [Abstract][Full Text] [Related]
13. Lymphocyte subsets and specific T-cell immune response in thalassemia.
Pattanapanyasat K; Thepthai C; Lamchiagdhase P; Lerdwana S; Tachavanich K; Thanomsuk P; Wanachiwanawin W; Fucharoen S; Darden JM
Cytometry; 2000 Feb; 42(1):11-7. PubMed ID: 10679738
[TBL] [Abstract][Full Text] [Related]
14. Comparative immunophenotypic features of EBV-positive and EBV-negative atypical lymphocytosis.
Hudnall SD; Patel J; Schwab H; Martinez J
Cytometry B Clin Cytom; 2003 Sep; 55(1):22-8. PubMed ID: 12949956
[TBL] [Abstract][Full Text] [Related]
15. [Interferon therapy effects on activation of T-lymphocytes in patients with systemic lupus erythematosus].
Stanislav ML; Balabanova RM; Nikonova MF; Litvina MM; Iarilin AA
Ter Arkh; 2000; 72(5):44-9. PubMed ID: 11109620
[TBL] [Abstract][Full Text] [Related]
16. Limited effect of eicosapentaenoic acid on T-lymphocyte and natural killer cell numbers and functions in healthy young males.
Miles EA; Banerjee T; Wells SJ; Calder PC
Nutrition; 2006 May; 22(5):512-9. PubMed ID: 16600816
[TBL] [Abstract][Full Text] [Related]
17. Inosine Acedoben Dimepranol promotes an early and sustained increase in the natural killer cell component of circulating lymphocytes: A clinical trial supporting anti-viral indications.
Rumel Ahmed S; Newman AS; O'Daly J; Duffy S; Grafton G; Brady CA; John Curnow S; Barnes NM; Gordon J
Int Immunopharmacol; 2017 Jan; 42():108-114. PubMed ID: 27912146
[TBL] [Abstract][Full Text] [Related]
18. Modulation of natural killer (NK) receptors on NK (CD3-/CD56+), T (CD3+/CD56-) and NKT-like (CD3+/CD56+) cells after heart transplantation.
Aguilar P; Mathieu CP; Clerc G; Ethevenot G; Fajraoui M; Mattei S; Faure GC; Bene MC
J Heart Lung Transplant; 2006 Feb; 25(2):200-5. PubMed ID: 16446221
[TBL] [Abstract][Full Text] [Related]
19. [An analysis of immunophenotyping of peripheral lymphocytes in adult patients with infectious mononucleosis and chronic active Epstein-Barr virus infection].
Xie J; Wang HL; Qiu ZF; Li TS
Zhonghua Nei Ke Za Zhi; 2016 Jun; 55(6):455-9. PubMed ID: 27256608
[TBL] [Abstract][Full Text] [Related]
20. The Frequency and clinical Implications of Lymphocyte Subsets and Circulating Plasma Cells in Newly Diagnosed Multiple Myeloma Patients.
Zahran AM; Sayed MM; Shafik EA; Khallaf SM; Mohamed WM; Hetta HF
Egypt J Immunol; 2019 Jul; 26(2):117-131. PubMed ID: 31926501
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
